Hacking The Brain: Czech Neurotech Startup Stimvia Brings AI To Non-Invasive BCI
Lukáš Doskočil, founder and CEO of Stimvia
Stimvia, a Czech startup founded by medical device executive Lukáš Doskočil, has developed a non-invasive neuromodulation system that uses electrical pulses to stimulate deep brain structures through the leg. Called URIS, the technology was first deployed to treat overactive bladder, but now shows early promise for a range of neurological disorders including Parkinson's disease, multiple sclerosis, and Restless Leg Syndrome, which is treated with Parkinson's medication.
A patient secures URIS sensors behind the knee, where a nerve provides access to the central nervous ... More system.
At the core of Stimvia's approach is what Doskočil calls a "hack" into the brain via the peroneal nerve behind the knee. The URIS system uses proprietary non-invasive electrodes to send electrical signals along afferent nerve pathways to the prefrontal cortex, eliminating the need for invasive implants or surgery. "We did a mechanistic study using functional MRI and showed stimulation effects in deep brain structures," Doskočil told me. "That's never been done non-invasively before."
Patients can easily control the intensity and duration of the treatment.
Pilot studies testing the Stimvia URIS device for treating Parkinson's disease have turned heads in the neurology and urology communities. A study conducted at Ostrava University Hospital found that Parkinson's patients using URIS experienced measurable reductions in resting tremor and improvements in quality of life. 'Patients showed marked improvement in motor symptoms and overall well-being, with quality-of-life scores surpassing clinically meaningful thresholds. All without serious side effects,' said Professor David Skoloudik, Vice-Dean for Research at Ostrava University's Medical Faculty. A separate clinical paper notes URIS® may outperform traditional sacral and tibial nerve stimulation in treating bladder dysfunction without the needles or surgery.
Stimvia's URIS device is connected to a companion app that collects data from each session, monitors patient symptoms, and adapts the stimulation protocol accordingly. Its latest version uses an AI-driven virtual assistant to optimize electrode placement and fine-tune pulse parameters in real time. "You could call it a virtual doctor," Doskočil said. It personalizes treatment using real-time body feedback, which represents a breakthrough for non-invasive therapy.'
Stimvia's non-invasion URIS treatments are also painless. Patients are able to read, watch tv, or ... More even nap while undergoing treatment.
The field is dominated by billion-dollar U.S. companies like Medtronic and Abbott. Boston Scientific last year bought Stimiva's competitor, Axonics, which also treats overactive bladder disorders, for almost $4B. Stimvia is small but agile. With 15 employees and manufacturing based in Pardubice, CZ, the company has already raised $8 million and is preparing a Series A round. It has shipped more than 200 units and is actively expanding across Europe. Denmark was the first foreign market, but the device is now being adopted in clinics across France, Italy, Spain, Greece, the Netherlands, and the UK. Stimvia recently earned MDR certification from German standards body TÜV SÜD, opening the door to reimbursement in EU healthcare systems and clearing a path toward FDA approval.
Patients can control the intensity and duration of the URIS treatment for Parkinson's symptoms.
The implications go beyond overactive bladder, which affects 500 million people globally and is quietly responsible for a massive adult diaper industry and associated greenhouse gas emissions. 'The actual number is likely much higher and may approach the 1 billion mark, given a prevalence of around 16% among adults—surpassing even diabetes,' Doskočil told me. 'However, it remains a highly stigmatized condition that will become increasingly significant as the population ages.'
According to Wired Czechia, investors have taken notice. Stimvia is backed by local venture funds like Xenocles, Venture Capital Partners and Purple Ventures, with another five to ten million in new funding expected soon. But Doskočil, who is not a doctor but trained in economics and medical technology, says Europe's fragmented reimbursement landscape makes it harder to scale. That's why the company is now setting its sights on the United States, where one FDA approval covers 50 states.
'It's not easy to innovate in Europe,' Doskočil told me. 'Every country is different. The U.S. is one market. That changes everything.' Stimvia is hiring a commercial team in Miami, including a new chief commercial officer with prior experience at LivaNova. The U.S. rollout will also include investigator-led trials, with hopes of replicating European success in a much larger market.
Stimvia's technology offers new hope for patients with a range of brain-related conditions, from Parkinson's tremors to overactive bladder. As Doskočil says, 'OAB is a brain disease masquerading as a bladder problem,' highlighting how many disorders traditionally treated by symptoms are actually rooted deeply in the brain. With non-invasive neuromodulation, Stimvia is pioneering a new way to treat these conditions, changing lives without surgery or implants.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
32 minutes ago
- Forbes
Dispute Resolution: Is Decentralization The Answer?
Saro McKenna is the CEO of Dacoco GmbH and cofounder of Alien Worlds. Although the godfather of online dispute resolution, Ethan Katsh, once observed that "the power of technology to resolve disputes is exceeded by the power of technology to generate disputes," as human beings, we cannot help ourselves. Even the prospect of AI sentience and bots capable of overpowering their flesh-and-bone creators cannot halt our penchant for relentlessly leveraging tech to achieve advancement in one area or another. As far as disputes are concerned, the technology that has increasingly been used to intercede is blockchain. This is no surprise. Of all the suggested use cases for a censor- and tamper-proof decentralized digital ledger, jurisprudence rightly ranks high. Over the past decade, many technologists have attempted to adapt traditional legal concepts and resolve conflicts on-chain, with mixed success. So, why is blockchain considered the best "lawtech" tool to settle disputes? Decentralized dispute resolution is appealing because of its ability to bypass centralized authorities that are prone to bias or bureaucracy. Smart contracts and empowered jurors streamline arbitration, handling all kinds of disputes with transparency. As traditional legal systems often prove unwieldy or unfit for specific disagreements, DDR offers fast, fair outcomes. Evidently, there are many factors that entice developers to build Web3 protocols that are concerned with dispute resolution. Blockchain, being apolitical, decentralized and transparent, is perceived to be perhaps the best vehicle for administering justice when two or more parties are in disagreement. These parties can consist of individuals or even companies and governments. Perhaps blockchain is too broad a term, however, because it is often specific features of certain chains, like decentralized autonomous organizations (DAOs) and smart contracts, that prove useful in an arbitration capacity. The economic incentives baked into blockchains are another important consideration, with the general idea being that users can become jurors, reviewing evidence and voting for the party they believe is right. In blockchain-based systems, jurors are usually financially motivated to make a sound judgment, i.e., one that accords with the majority. Kleros is one of the earliest examples of a decentralized adjudication system, one that uses jurors and game theory to produce judgments in a secure and inexpensive way. Founded in 2017, the Ethereum-based arbitration service was designed to "resolve any kind of dispute," building on the work of early Web3 pioneers like Vitalik Buterin and Paul Sztorc, whose idea to use Schelling Point-based incentives for blockchain oracles gave rise to the notion of "decentralized truth-telling." In the case of Kleros, the probability of crowdsourced jurors being selected is proportional to the amount of tokens staked. Staking, then, signifies one's willingness to participate in the adjudication process in contrast to the traditional court system, where jurors are selected at random. Arbitration fees, meanwhile, make it difficult for attackers to spam the system by creating frivolous disputes. Many similar protocols appeared around this time, among them Jur (2018) and Aragon (2016). While the former focused on enterprise use cases and selected jurors based on their reputation rather than token stake, the latter favored a subscription model and was intended for arbitration within DAOs themselves. Although they held promise, neither project is currently actively maintained. The popularization of DeFi around 2020 prompted renewed interest in dispute resolution, most notably in the case of the UMA protocol's Data Verification Mechanism (DVM), which resolves disputes about the price of a synthetic token derivative contract. This type of system, of course, has a much narrower focus than projects like Kleros, which seek to be multipurpose courts. A watershed moment for DDR occurred in 2021 when a Mexican court enforced a decentralized arbitration award governed by Kleros, which related to a real estate dispute. Last year, Mexico also passed the General Law of Alternative Dispute Resolution Mechanisms, the first national legislation recognizing decentralized justice as a valid dispute resolution system. Central to the premise of DDR is the idea that arbiters can come to a fair and transparent judgment based on the available evidence: the wisdom of the crowd, enforced on-chain. Arbiters play a key role in the recently unveiled Worker Proposal System of blockchain-based metaverse Alien Worlds (which I cofounded), which is centered on the activity of various DAOs. While the system empowers users to suggest and execute new projects, arbiters act as neutral mediators in any disputes that arise. For example, arbiters can step in and cast a deciding vote when there is a disagreement about project milestones. In this particular arbitration model, a blockchain escrow account is also used since the Worker Proposal System is designed to furnish the awarded party with tokens for meeting pre-agreed targets. Arbiters must complete an identity verification process, demonstrate a solid understanding of the Alien Worlds ecosystem, commit to a minimum term of four months to ensure continuity and dedicate specific weekly hours to their role. They are also paid a set rate for performing this role. As the primary contributor to Alien Worlds, my company, Dacoco, takes a notable approach to dispute resolution by blending Web2 and Web3 concepts in a unique way. While disputes are enforced on-chain, and a DAO system transparently manages worker proposals, the arbiter functions similarly to an independent mediator in any traditional legal process. In other words, Dacoco is not relying entirely on blockchain to adjudicate. In most cases, protocols promising to administer decentralized justice have failed to achieve their objectives, whether due to technical, market or other challenges. This is a great shame because on-chain arbitration offers many advantages over a sluggish legal system that is notorious for its inequity (the most powerful people can afford the best litigators) and complexity. Although decentralized dispute resolution has yet to gain widespread adoption, and many challenges remain, expect lawtech solutions to grow more sophisticated over time and for traditional courts to follow Mexico's lead in recognizing such systems. In a sense, it is analogous to the way in which the financial world has gradually recognized Bitcoin, a consequence of the number of individuals storing their wealth in the network. Ultimately, the best and most efficient solutions have a tendency to break into the spotlight. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
37 minutes ago
- Yahoo
A simple blood test could offer first reliable diagnosis for ME
A simple blood test could provide the first reliable diagnosis for myalgic encephalomyelitis (ME) and end the lengthy process of trying to identify the debilitating condition, scientists have found. It's thought more than 400,000 people in the UK suffer with the condition, also known as chronic fatigue syndrome (CFS). Pain, brain fog and extreme low energy that does not improve with sleep are just some of the symptoms of ME. There is no cure and the cause is unknown. Currently the only way to diagnose it is by ruling out other illnesses – a long process that can mean patients wait years for a diagnosis. However, researchers at the University of Edinburgh believe they have made a breakthrough. The study published in the Journal EMBO Molecular Medicine used data from the UK Biobank – a large-scale resource based on the health data and biological samples of 500,000 UK participants. Researchers compared blood samples from 1,455 ME patients with more than 131,000 healthy people. They identified differences in cell counts and molecules that differed in concentrations between the two. The differences in samples for the ME patients were related to chronic inflammation, insulin resistance and liver dysfunction. These findings were compared and replicated in data from a group of American patients and healthy controls. Researchers found 116 'biomarkers' for ME in the blood of men and women with the condition. This is a key finding because the condition affects men and women differently. Professor Chris Ponting, of the university's Institute of Genetics and Cancer, said: 'For so long people with ME/CFS have been told it's all in their head. It's not. We see [it] in their blood. 'Evidence of a large number of replicated and diverse blood biomarkers that differentiate between ME/CFS cases and controls should dispel any lingering perception it is caused by deconditioning and exercise intolerance.' These biomarkers did not change when the participants were any more active – consistent with the view graded exercise therapy, which aims to gradually increase activity levels, is unlikely to be helpful. In fact, the largest differences were seen in people who reported post-exertional malaise. This is when the symptoms of the condition become worse even after minor physical effort. Dr Sjoerd Beentjes, of the university's School of Mathematics, said: 'Blood differences are sometimes attributed to reduced activity levels rather than ME/CFS directly. Our study provides strong evidence ME/CFS affects blood traits through paths other than activity.' However, this research is still at an early stage and there is no guarantee a test will be possible, study authors stressed. Professor Kevin McConway, Emeritus Professor of Applied Statistics, Open University, who was not part of the study, said: 'There is a lot more to do.' 'These findings could help in finding a set of blood biomarkers that can reasonably reliably distinguish people with ME/CFS from those who do not have that condition, but that, without a lot of further work, the findings do not in themselves provide such a set of biomarkers,' he added.
Yahoo
38 minutes ago
- Yahoo
BBC Threatens Injunction Against Perplexity AI
Perplexity is in hot water after the BBC accused the AI search startup of quietly scraping its entire archive to train its default model, warning that it'll head to court if those copies aren't deleted and a compensation plan isn't on the table. Warning! GuruFocus has detected 4 Warning Signs with NVDA. In a letter leaked to the Financial Times, the U.K. broadcaster gave Perplexity CEO Aravind Srinivas an ultimatum: stop hoovering up BBC content, erase whatever's already stored for AI training, and figure out how much you'll pay for infringing on our IP. Backed by Nvidia (NASDAQ:NVDA) and Amazon (NASDAQ:AMZN) Co-Founder Jeff BezosPerplexity didn't hold back in its response, branding the BBC's move manipulative and opportunistic and suggesting the broadcaster just doesn't get how web tech and copyright law actually work. This isn't their first brush with big publishersback in October, the New York Times sent a cease?and?desist over similar scraping claimsso it underscores a bigger headache for model builders: litigation risk is growing just as fast as the data they're hungry for. Some of the deep-pocketed players are sidestepping this by licensing content outright, but for cash-strapped startups, that could mean tighter margins and slower rollouts if court dates start piling up. This article first appeared on GuruFocus.
